Sezer O - Search Results

1

Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.

Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K. Schmid P, et al. Among authors: sezer o. Anticancer Drugs. 1999 Aug;10(7):625-31. doi: 10.1097/00001813-199908000-00001. Anticancer Drugs. 1999. PMID: 10507311 Clinical Trial.

2

Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.

Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K. Akrivakis K, et al. Among authors: sezer o. Anticancer Drugs. 1999 Jul;10(6):525-31. doi: 10.1097/00001813-199907000-00003. Anticancer Drugs. 1999. PMID: 10885899 Clinical Trial.

3

Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.

Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K. Sezer O, et al. Invest New Drugs. 2001;19(1):101-4. doi: 10.1023/a:1006478702342. Invest New Drugs. 2001. PMID: 11291828

4

Prediction of response to hormonal treatment in metastatic breast cancer.

Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K. Schmid P, et al. Among authors: sezer o. Oncology. 2002;63(4):309-16. doi: 10.1159/000066224. Oncology. 2002. PMID: 12417785 Review.

5

Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?

Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Schweigert M, Stuschke M, Fleischhacker M, Siebert G, Mergenthaler HG, Werner TG, Sezer O, Possinger K. Beinert T, et al. Among authors: sezer o. Eur J Med Res. 1999 Aug 25;4(8):328-34. Eur J Med Res. 1999. PMID: 10471544

6

Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia.

Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler HG, Possinger K. Sezer O, et al. Ann Hematol. 1999 Oct;78(10):475-7. doi: 10.1007/s002770050602. Ann Hematol. 1999. PMID: 10550560 Review.

7

Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.

Lüftner D, Wagner K, Dingeldein G, Haas A, Sezer O, Mergenthaler HG, Wernecke KD, Possinger K. Lüftner D, et al. Among authors: sezer o. Anticancer Res. 1999 Jul-Aug;19(4C):3583-90. Anticancer Res. 1999. PMID: 10629656 Clinical Trial.

8

New therapeutic approaches in primary systemic AL amyloidosis.

Sezer O, Eucker J, Schmid P, Possinger K. Sezer O, et al. Ann Hematol. 2000 Jan;79(1):1-6. doi: 10.1007/s002770050001. Ann Hematol. 2000. PMID: 10663614 Review.

9

Detection of HMGI-C in the peripheral blood of breast cancer patients.

Sezer O, Langelotz C, Blohmer JU, Schmid P, Akrivakis K, Possinger K. Sezer O, et al. Eur J Cancer. 2000 Oct;36(15):1944-8. doi: 10.1016/s0959-8049(00)00199-4. Eur J Cancer. 2000. PMID: 11000575

10

Novel approaches to the treatment of primary amyloidosis.

Sezer O, Niemöller K, Jakob C, Langelotz C, Eucker J, Possinger K. Sezer O, et al. Expert Opin Investig Drugs. 2000 Oct;9(10):2343-50. doi: 10.1517/13543784.9.10.2343. Expert Opin Investig Drugs. 2000. PMID: 11060811 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters